ONCOLYTICS BIOTECH INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 |
|---|---|---|---|
| Income Statement | |||
| Research and development | $13.3M | $15.4M | — |
| Operating expenses | $28.7M | $25.5M | — |
| Operating income | -$28.7M | -$25.5M | — |
| Pretax income | -$28.7M | -$22.7M | — |
| Income tax expense | $79,000 | $95,000 | — |
| Net income | -$28.8M | -$22.8M | — |
| Balance Sheet | |||
| Cash and equivalents | $5.2M | $11.1M | — |
| Current assets | $6.8M | $12.4M | — |
| Total assets | $7.6M | $13.4M | — |
| Current liabilities | $6.1M | $4.9M | — |
| Total liabilities | $11.4M | $10.1M | — |
| Stockholders' equity | -$3.8M | $3.3M | $19.6M |
| Cash Flow Statement | |||
| Cash from operations | -$20.1M | -$19.9M | — |
| Depreciation and amortization | $70,000 | $87,000 | — |
| Stock-based compensation | $3.1M | $2.0M | — |
| Capital expenditure | $6,000 | $174,000 | — |
| Free cash flow | -$20.1M | -$20.1M | — |
Shares outstanding 119.4M · Free float 100.0%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.